古代经典名方3.1类新药

Search documents
佛慈制药:积极与兰州大学等科研院所合作,开展3项古代经典名方3.1类新药开发
Mei Ri Jing Ji Xin Wen· 2025-08-20 10:52
Core Insights - The company emphasizes its commitment to research and innovation in the pharmaceutical sector, particularly in the development of innovative drugs [2] Group 1: Research and Development - The company is increasing its investment in research and development, collaborating with institutions such as Lanzhou University and the Chinese Academy of Traditional Chinese Medicine [2] - It is working on the development of three new drugs based on ancient classic formulas, classified as Category 3.1 new drugs, to promote the inheritance and innovation of traditional Chinese medicine [2] Group 2: Product Development - The company is conducting secondary research and development on existing unique and specialty products, including Shenrong Guoben Shaowan, Compound Huangqi Jianpi Oral Liquid, Shugan Xiaojie Wan, and Xiaozhi Wan [2] - The focus of this research includes exploring the efficacy of active ingredients, identifying new functions, and validating clinical data to accelerate the cultivation of major products and enhance market competitiveness [2]